Why ResMed Stock Is Back in Focus After Board and Auditor Changes
ResMed (RMD) is drawing attention after announcing two governance moves. Carol Burt will become Lead Director in November 2026, and the company has also replaced KPMG with PricewaterhouseCoopers as its independent auditor.
See our latest analysis for ResMed.
ResMed’s governance updates arrive as momentum in the share price has recently turned positive. The stock has a 1 month share price return of 18.56%, while the year to date share price return is down 5.43%. The 1 year total shareholder return is down 18.14%, compared with a 3 year total shareholder return of 47.30%.
If this kind of governance driven story has your attention, it can also be useful to scan for other healthcare companies applying data and automation, including those in 41 healthcare AI stocks
ResMed shares trade at a discount to both analyst targets and an estimated fair value, even after the recent rebound and governance changes. Is that gap a sign of undue caution, or a reasonable response to the risks?
Most Popular Narrative: 6.6% Undervalued
On the latest numbers, ResMed closed at $231.52, while the most widely followed narrative points to a fair value of about $247.93 using a 7.42% discount rate.
Strategic investments in expanding the diagnosis and treatment funnel, including acquisitions like VirtuOx, Ectosense, and Somnoware, are improving patient flow from screening to therapy, positioning ResMed to capture a larger share of the substantial underpenetrated global sleep apnea and respiratory market, supporting long-term revenue growth.
Want to see what powers that fair value for ResMed? The narrative leans heavily on steady revenue gains, resilient profit margins, and a future earnings multiple that assumes investors pay up for consistency.
Result: Fair Value of $247.93 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, ResMed’s story could shift quickly if Philips Respironics returns to the U.S. market in 2027 or if ventilator component constraints weigh more heavily on earnings.
Find out about the key risks to this ResMed narrative.
Next Steps
If the mixed sentiment around ResMed leaves you uncertain, now is a good time to review the numbers yourself and decide where you stand. To see what investors currently view as the key positives, review the 4 key rewards
Looking for more ResMed style investment ideas?
If ResMed has sharpened your focus on quality opportunities, do not stop here. The right screen could surface stocks that fit your strategy before others notice.
- Target strong cash generation and pricing power by reviewing companies flagged in the 48 high quality undervalued stocks.
- Prioritise resilience and downside protection by checking out the 75 resilient stocks with low risk scores.
- Hunt for potential early movers with robust fundamentals using the screener containing 18 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com